PRA International Completes Buyout

Thursday, December 13, 2007 12:58 PM

Genstar Capital, a private equity group based in San Francisco, has completed its acquisition of PRA International, paying $797 million for the Raleigh, N.C.-based contract research organization (CRO).

During a conference call in July, PRA executives said that Genstar will invest in the company to accelerate plans for expanding the firm’s service offerings and broaden its geographic footprint.

In response to an analyst’s question during the call, Terrance Bieker, chief executive officer of PRA, stated its board of directors came to the conclusion that the right course of action was to provide its shareholders with an immediate premium on their investment.

“This decision is driven by value and reward, and it was determined that this is a right price for the shareholders. So, the decision for doing this is not so the company can perform better in a different venue, it was done because it is a very good return to the shareholders,” Bierker said.

Shareholders will receive a cash buyout of $30.50 per common share. That would be a 24% premium over PRA’s average closing price for three months prior to the July announcement.

Genstar was an early investor in PRA and already owned 12.8% of the company. In June 2001, PRA’s executive management team completed a buyout of the company, partly with financial backing from Genstar. The company went public in November 2004.

Share:          
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs